Hot Topics Discussed in Covance Spring Webinars

Unlock opportunities for your clinical research programs and deliver results that Covance Spring Webinars Video Nash Diabetic Heart Biomarkersmatter.
We’re excited to be on the cutting edge of drug development solutions. Take a look at past and future webinar topics and leverage our experience.

Kidney Biomarkers in Drug Development

Experts discuss emerging translational biomarkers and insights into evaluation of nonclinical urine biomarker data.  We’ll also discuss translational biomarkers in clinical trials for recent renal-related diseases/mechanisms. Continue reading

Computerworld Names Dimitris Agrafiotis of Covance a 2017 Premier 100 Technology Leader

Agrafiotis’ Leadership in Bringing Xcellerate® Informatics to Market Demonstrates How Software Can Improve Health and Improve Lives

IDG’s Computerworld recently recognized Dimitris Agrafiotis, PhD, chief data officer and Computerworld Dimitris Agrafiotis head of technology products for Covance Drug Development, as a 2017 Premier 100 Technology Leaders honoree. This year’s Premier 100 spotlights 100 leaders from both the technology and business sides of companies for their exceptional technology leadership and innovative approaches to business challenges. Covance is the drug development business of LabCorp.

“The Premier 100 awards program highlights the exceptional work of an elite group of IT executives who are leading their organizations through times of unprecedented change. They are using technology to drive high-stakes business projects and create dynamic growth in their organizations,” said Scot Finnie, editor in chief of Computerworld.

“These 100 men and women are not only strategic business thinkers, but also team leaders who recognize the importance of recruiting and retaining the brightest talent to enable digital transformation and harness the opportunities of cloud, big data, mobile and social. We’re pleased to recognize their leadership and honor their achievements.” Continue reading

Shape New Career Possibilities at Covance

With unique career opportunities to advance the future of drug development, Covance employees are part of an exciting journey, delivering novel and comprehensive solutions to advance medicines from early research to clinical trials and beyond.

What does it mean to work with a company that not only invests in you, but carries the vision of creating a healthier future? See how Covance enables Extraordinary Paths, Exceptional People.

To learn more about how you can make a difference in drug development and to explore Covance career opportunities, please visit careers.covance.com Continue reading

An Insider’s View on Working for Covance

Since starting my drug development journey as quality assurance manager in a laboratory Working for Covance that would later become part of Covance to now serving as the CEO, I’ve witnessed our industry’s notable shift to support more nimble drug development. From improved trial design to companion diagnostics and more predictive insights fueled by advanced informatics, it’s exciting to see bold ideas enable smarter decisions and speed the introduction of groundbreaking therapies.

Progress is evident in many areas—starting at early phases through market access—but one factor remains constant throughout the years: our hard-working employees continue to advance innovation. They are the reason we can deliver unique perspectives that shape new solutions and carry out the vision of a healthier future. Continue reading

The Development Landscape for Non-Alcoholic Steatohepatitis

The Development Landscape for Non-Alcoholic SteatohepatitisThe Development Landscape for Non-Alcoholic Steatohepatitis Q&A

Q&A with Claudia Filozof, MD, PhD, Senior Medical Director in the Phase II-IV Cardiovascular/Metabolic Group and Richard Williams, PhD, JD, Executive Strategist,  Global Regulatory Affairs

Is this a good time to develop a NASH drug, and if so, why?

Claudia: Yes, it’s a very good time. There are multiple companies starting NASH development, and there is a huge unmet medical need with no treatment approved so far. Health authorities also have shown a lot of interest in supporting companies to speed up development. If you have the right compound, there are multiple advantages to starting a NASH program.

Richard: The cost to society will be enormous if we can’t treat this disease. I think most pharmaceutical companies, big and small, see this as a substantial unmet medical need. With this unmet medical need,  regulatory agencies can grant  conditional approval (accelerated approval in the US), where the drug is approved for marketing with the condition that the company later shows it has a clinical benefit based on clinical  outcomes. Continue reading

Investing in Today’s CRA Talent to Ensure a Stronger Tomorrow

The Importance of Clinical Research Associate Training to Support Effective Trials

The clinical trial landscape is witnessing an increase in Phase III trials that average more than 3,500 patients. As more of these large trials continue to emerge, many contract research organizations (CROs) and sponsors are struggling to recruit Covance Clinical Research Associatesqualified clinical research associates (CRAs) to support the influx of work.

Lack of experienced talent represents one of the main challenges facing the market, impacting sponsors and CROs alike with increased costs and extended timelines. Yet the urgent need for qualified CRAs will continue given that the demand in the field is projected to grow by 36.4% from 2012 to 2022[1] in the US, an issue also reflected worldwide.

Continue reading

Are you ready for ISO 15189:2012 to make a difference in your bottom line?

Is it possible to get more efficiency in your conventional and specialty tests while maintaining ongoing quality? ISO 15189:2012 accreditation answers this question by delivering a comprehensive approach to quality management in medical, central Covance ISO 15189:2012 accreditation blogand referral laboratories. Not only can these standards ensure quality, but they can reduce your risk of costly delays and ultimately save money in your trials.

“It’s no surprise that sponsors are concerned about the risk of regulatory findings and increasingly requesting ISO-accredited labs,” said Paul Kirchgraber, Vice President and Global General Manager at Covance Central Laboratory Services. “They need a demonstration of increasing quality—and savings—across their outsource vendors. Adopting ISO 15189:2012 is a powerful way to highlight our broad quality standards that meet or exceed their expectations.”

Continue reading

Vaccine and Novel Immunotherapeutic Development: A Personal Quest

Like my colleagues at Covance, my work ultimately contributes to improving Vaccine and Novel Immunotherapeutic Development Covance Bloghealthcare and patients’ lives. Our efforts to accelerate fresh approaches towards effective treatments became deeply personal in 2007 when my oldest sister, Vicki, was diagnosed with advanced Triple Negative Breast Cancer (TNBC).

From her initial diagnosis, my sister was full of vitality and enjoyed a high quality of life due in part to several of the novel treatments that Covance had helped develop. She even participated in a long-term clinical trial involving an angiogenesis-inhibitor, in addition to traditional chemotherapy, during her early treatment.

Vicki became a student of her diagnosis, reading countless journal articles on the rapid advances in scientific understanding. When her health took a sharp decline, she asked for my support in helping her gain access to a new trial focused on the immune system. She wanted to do whatever she could to help others find a better treatment, or even a cure, for TNBC. Ultimately, she was too weak to make the journey to participate in a cutting-edge clinical trial. Vicki died on October 1st, 2013.

Continue reading